PAVM

PAVmed Inc

PAVM, USA

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York

https://www.pavmed.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PAVM
stock
PAVM

PAVmed (NASDAQ:PAVM) Price Target Lowered to $17.00 at Ascendiant Capital Markets Defense World

Read more →
PAVM
stock
PAVM

New Analyst Forecast: $PAVM Given $17 Price Target Quiver Quantitative

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$11

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

198.80

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-17,685.86 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-16,622.45 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-17,980.00 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.34

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 6.56% of the total shares of PAVmed Inc

1.

First Manhattan Co. LLC

(3.2558%)

since

2025/06/30

2.

Geode Capital Management, LLC

(0.4043%)

since

2025/06/30

3.

Vanguard Group Inc

(0.3716%)

since

2025/06/30

4.

Vanguard Institutional Extnd Mkt Idx Tr

(0.3542%)

since

2025/07/31

5.

BlackRock Inc

(0.3313%)

since

2025/06/30

6.

Fidelity Extended Market Index

(0.304%)

since

2025/07/31

7.

CapTrust Financial Advisors

(0.2966%)

since

2025/06/30

8.

LPL Financial Corp

(0.2532%)

since

2025/06/30

9.

Jane Street Group LLC

(0.2402%)

since

2025/06/30

10.

Obermeyer Asset Management Co

(0.098%)

since

2025/06/30

11.

State Street Corp

(0.0951%)

since

2025/06/30

12.

Fidelity Series Total Market Index

(0.0676%)

since

2025/07/31

13.

Northern Trust Corp

(0.0534%)

since

2025/06/30

14.

XML Financial, LLC

(0.0459%)

since

2025/06/30

15.

Extended Equity Market Fund K

(0.0428%)

since

2025/06/30

16.

UBS Group AG

(0.0399%)

since

2025/06/30

17.

Fidelity Total Market Index

(0.0358%)

since

2025/07/31

18.

Northern Trust Extended Eq Market Idx

(0.031%)

since

2025/06/30

19.

NT Ext Equity Mkt Idx Fd - L

(0.031%)

since

2025/06/30

20.

Spartan Total Market Index Pool G

(0.0305%)

since

2025/07/31

21.

CWM, LLC duplicate

(0.0292%)

since

2025/06/30

22.

Morgan Stanley - Brokerage Accounts

(0.0229%)

since

2025/06/30

23.

Tower Research Capital LLC

(0.0205%)

since

2025/06/30

24.

NT Ext Equity Mkt Idx Fd - NL

(0.0201%)

since

2025/06/30

25.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0156%)

since

2025/06/30

26.

State St US Extended Mkt Indx NL Cl C

(0.0131%)

since

2025/08/31

27.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0087%)

since

2025/06/30

28.

Vanguard U.S. Eq Idx £ Acc

(0.0082%)

since

2025/07/31

29.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0074%)

since

2024/12/31

30.

Wells Fargo & Co

(0.0066%)

since

2025/06/30

31.

SSgA U.S. Total Market Index Strategy

(0.0055%)

since

2025/03/31

32.

Extended Equity Market Fund M

(0.0054%)

since

2025/06/30

33.

Atlantic Trust Group, LLC

(0.0038%)

since

2025/06/30

34.

SIMPLEX TRADING, LLC

(0.0026%)

since

2025/06/30

35.

State St US Ttl Mkt Indx NL Cl A

(0.0024%)

since

2025/08/31

36.

Northern Trust Wilshire 5000

(0.0023%)

since

2025/06/30

37.

Spartan Extended Market Index Pool F

(0.0021%)

since

2025/07/31

38.

BNYM Mellon SL Market Completion UC1

(0.002%)

since

2025/06/30

39.

Hanson Mcclain Inc

(0.0013%)

since

2025/06/30

40.

JONES FINANCIAL COMPANIES LLLP

(0.0011%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.02

EPS Estimate

-0.2

EPS Difference

0.18

Surprise Percent

90%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4.5)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(3)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.